Economic consequences of the progression of rheumatoid arthritis in Sweden

Arthritis and Rheumatism

Volumn 42, Issue 2, 1999, Pages 347-356

  Kobelt, Gisela ^a   Eberhardt, Kerstin ^b   Jönsson, Linus ^c   Jönsson, Bengt ^c  

^a Health Dynamics International   (United Kingdom)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; CHLOROQUINE; CYCLOSPORIN A; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE;

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; ECONOMIC ASPECT; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIMULATION; SWEDEN;

ARTHRITIS, RHEUMATOID; COHORT STUDIES; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; HEALTH STATUS; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; QUESTIONNAIRES; SWEDEN; TREATMENT OUTCOME; WORK CAPACITY EVALUATION;

EID: 0033003967     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199902)42:2<347::AID-ANR18>3.0.CO;2-P     Document Type: Article

References (44)

1. Pincus T. The underestimated long term medical and economic consequences of rheumatoid arthritis. Drugs 1995;50 Suppl 1:1-14.
2. Meenan RF, Yelin EH, Nevitt M, Epstein WV. The impact of chronic disease: a sociomedical profile of rheumatoid arthritis. Arthritis Rheum 1981;24:544-9.
3. Katz PP. The impact of rheumatoid arthritis on life activities. Arthritis Care Res 1995;8:272-8.
4. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;27:864-72.
5. Sherrer YS, Bloch DA, Mitchell DM, Young DY, Fries JF. The development of disability in rheumatoid arthritis. Arthritis Rheum 1986;29:494-500.
6. Vanderbroucke JP, Hazevoet HM, Cats A. Survival and cause of death in rheumatoid arthritis: a 25-year prospective follow-up. J Rheumatol 1984;11:158-61.
7. Raskers JJ, Cosh JA. The natural history of rheumatoid arthritis over 20 years: clinical symptoms, radiological signs, treatment, mortality and prognostic significance of early features. Clin Rheumatol 1987;6 Suppl 2:5-11.
8. Meenan RF, Yelm EH, Henke CJ, Curtis DL, Epstein WV. The costs of rheumatoid arthritis: a patient-oriented study of chronic disease costs. Arthritis Rheum 1978;21:827-33.
9. Lubeck DP, Spitz PW, Fries JF, Wolfe F, Mitchell DM, Roth SH. A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum 1986;29:488-93.
10. Yelin E, Meenan R, Newitt M, Epstein W. Work disability in rheumatoid arthritis: effects of disease, social and work factors. Ann Intern Med 1980;93:551-6.
11. Fex E, Larsson B-M, Nived K, Eberhardt K. Impact of rheumatoid arthritis on work status and social and leisure time activities in patients followed 8 years from onset. J Rheumatol 1997;25:44-50.
12. Reisine E, Goodenow C, Grady KE. The impact of rheumatoid arthritis on the homemaker. Soc Sci Med 1987;25:89-95.
13. Allaire SH, Prashker MJ, Meenan RF. The costs of rheumatoid arthritis. Pharmacol Econ 1994;6:513-22.
14. Johannesson M. Theory and methods of economic evaluation of health care. Boston: Kluwer Academic Publishers; 1996.
15. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
16. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd edition. New York: Oxford University Press, 1997.
17. Torrance GW. Measurement of health state utilities for economic appraisal: a review. J Health Econ 1986;5:1-30.
18. The EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
19. Torrance GW, Zhang Y, Feeny DH, Furlong WJ, Ban R. Multi-attribute value and utility functions for a comprehensive health status classification system. Toronto: McMasters University Research Report; 1992.
20. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada. Ottawa: CCOHTA; 1994.
21. Commonwealth Department of Human Services and Health. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including submissions involving economic analyses. Canberra: Australian Government Publishing Service; 1995.
22. Thompson MS, Liang MH. Examples of cost-benefit analysis: the rheumatic diseases. In: Costs and benefits of drug treatment. Munich: W Zuckschwerdt Verlag; 1990.
23. Bosi Ferraz M, Maetzel A, Bombardier C. A summary of economic evaluations published in the field of rheumatology and related disciplines. Arthritis Rheum 1997;40:1587-93.
24. Rittenhouse B. Uses of models in economic evaluations of medicines and other health technologies. London: Office of Health Economics; 1996.
25. Sonnenherg FA, Beck JR. Markov models in medical decision making. Med Decis Making 1993;13:322-38.
26. Krahn M, Gafni A. Discounting in economic evaluation of health care interventions. Med Care 1993;31:403-18.
27. Eherhardt K, Rydgren LC, Petersson H, Wollheim FA. Early rheumatoid arthritis - onset, course and prognosis over 2 years. Rheumatol Int 1990;10:135-42.
28. Ekdahl C, Eberhardt K, Andersson S-I, Svensson B. Assessing disability in rheumatoid arthritis: use of a Swedish version of the Stanford Health Assessment Questionnaire. Scand J Rheumatol 1988;17:263-71.
29. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol 1977;18:481-91.
30. Fex E, Jonsson K, Johnson U, Eherhardt K. Development of radiographic damage during the first 5-6 years of rheumatoid arthritis: a prospective follow-up study of a Swedish cohort. Br J Rheumatol 1996;35:1106-15.
31. Gudex C, Dolan P, Kind P, Williams A. Health state valuations from the general public using the visual analogue scale. Qual Life Res 1996;5:521-31.
32. Joensson B, Kaarela K, Kobelt G. Economic consequences of disease progression in rheumatoid arthritis in Finland: a Markov model. Stockholm School of Economics EFI research report no. 6574; 1997.
33. Nilsson CA, Carling K, Erlö CK, Myrén KJ. Vårdkostnader 1994: DRG-jämförelser av sjukhus och kliniker. Stockholm: SPRI rapport 437; 1996.
34. Federation of Swedish County Councils (Landstingsförbundet). Kostnader per intagen patient, vårddag, läkarbesök. Landstingens Ekonomi 1710. Stockholm: Landstingsförbundet; 1997.
35. Farmaceutiska Specialiteter i Sverige (FASS). Stockholm: Linfo Läkermedelsinformation AB; 1997.
36. Statistical Yearbook of Sweden, vol. 83. Stockholm: Statistika Centralburon; 1997.
37. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity. responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997;36:551-9.
38. Wolfe F, Hawley DJ. Measurement of the quality of life in rheumatic disorders using the EuroQol. Br J Rheumatol 1997;36: 786-93.
39. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC, for the Panel on Cost-Effectiveness in Health and Medicine. The role of cost-effectiveness analysis in health and medicine. JAMA 1996;276:1172-7.
40. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB, for the Panel on Cost-Effectiveness in Health and Medicine. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-8.
41. Siegel JE, Weinstein MC, Russell LB, Gold MR, for the Panel on Cost-Effectiveness in Health and Medicine. Recommendations for reporting cost-effectiveness analyses. JAMA 1996;276:1339-41.
42. Koopmanschap MA, Rutten FFH, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. Health Econ 1995;14:249-55.
43. Johannesson M, Meltzer D. Some reflections on cost-effectiveness analysis. Health Econ 1998;?:1-7.
44. Johannesson M, Karlsson G. The friction cost method: a comment. Journal of Health Economics 1997;7:249-55.